Company news
Syntara Limited (ASX:SNT) news
Syntara Limited news releases on 6ix. Latest, Nov 25, 2021: Security Purchase Plan
Press releases — page 2
Security Purchase Plan
November 24, 2021
FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study
November 8, 2021
Appendix 4C Cash Flow Report
October 27, 2021
PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
October 13, 2021
PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial
October 4, 2021
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears
August 30, 2021
PXS Grants Exclusive Option to Develop High Payload Inhaler
August 16, 2021
PXS Drug Decreases Tumour Burden in Liver Cancer Model
August 4, 2021
PXS Sells Australian Distribution Rights for A$2m
June 30, 2021
PXS Announces First Results in Bone Marrow Cancer Trial
June 29, 2021
Quarterly Activity Report
April 30, 2021
Appendix 4C - quarterly
April 30, 2021
Sale of Russian Distribution Rights
April 13, 2021
First Patient Enrolled - Clinical Trial for Cancer Treatment
February 21, 2021
Pharmaxis Exports CF Drug to US - US$3 Million Milestone
February 8, 2021
Quarterly Activity Report - December 2020
January 28, 2021
Pharmaxis Receives US$7m milestone from Chiesi
December 29, 2020
Pharmaxis Prioritises Clinical Program on Myelofibrosis
November 1, 2020
September Quarter 2020 Activity Report
October 29, 2020
Boehringer Ingelheim discontinues development of BI 1467335
September 6, 2020
Pharmaxis Awarded $1M Australian Government Grant
September 2, 2020
FDA Gives Green Light to Start Myelofibrosis Phase 2 Study
August 19, 2020
US$7 million Bronchitol Launch Milestone Brought Forward
August 4, 2020
Fourth Quarter Activity Report
July 30, 2020
Pharmaxis Quarterly Shareholder Update - March 2020
April 29, 2020
PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020
April 27, 2020
Quarterly Shareholder Update - December 2019
January 30, 2020
Pharmaxis Business Plan Update
December 17, 2019
Quarterly Shareholder Update - September 2019
October 30, 2019
FDA Provides Guidance on Bronchitol Approval Steps
October 27, 2019
Pharmaxis Receives $6.2m R&D Tax Incentive
October 16, 2019
Quarterly Shareholder Update - June 2019
July 25, 2019
Pathway to US Bronchitol Approval Clarified in FDA Response
June 19, 2019
US Advisory Committee Positive Recommendation on Bronchitol
May 8, 2019
Quarterly Shareholder Update - March 2019
April 29, 2019
Pharmaxis Commences Phase 1 LOX Clinical Trial
February 21, 2019
Quarterly Shareholder Update - December 2018
January 29, 2019
Pharmaxis Announces LOXL2 Program Phase 2 Ready
January 16, 2019
PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USA
December 19, 2018
Pharmaxis Announces First Relaunch Sales of Aridol in USA
December 12, 2018
Pharmaxis AGM - CEO Presentation
November 22, 2018
LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready
November 19, 2018
Pharmaxis Releases Positive Results of Phase 1 Clinical Tria
November 14, 2018
Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor
October 10, 2018
FDA Factory Approval and Relaunch of Aridol in US Market
August 14, 2018
Capital Raising Presentation
August 6, 2018
Trading Halt Announcement - System Upgrade
August 5, 2018
Quarterly Shareholder Update - June 2018
July 26, 2018
LOXL2 Program Attracts Strong Partner Interest at BIO18
June 13, 2018
Quarterly Shareholder Update - March 2018
April 30, 2018